EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Challenges and future directions for the use of GLP-1 receptor agonists in children and adolescents living with obesity

Giulio Equitani, Melania Manco

Obesity and Endocrinology · 06.01.2026 · 2 (1)

DOI: 10.1093/obendo/wjag009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Obesity and Endocrinology, online erschienen am 03.06.2026. Verfasst von Giulio Equitani und 1 weiteren Autor:innen. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To critically discuss evidence from randomized clinical trials investigating efficacy of glucagon-like peptide 1 receptor agonists in paediatric population and highlight important gap in knowledge while anticipating planned sponsored and investigator-initiated study.

Methods

Expert's non-systematic revision of the literature and opinion. Results and conclusion Intensive health behaviour and lifestyle treatment remains the foundation of care; however, obesity management medications, that is, glucagon-like peptide-1 receptor agonists, are increasingly integrated into management strategies for selected youth with moderate to severe obesity. While reductions in body mass index z-score have been found as clinically meaningful thresholds associated with cardiometabolic improvement, efficacy assessment must extend beyond weight-centric metrics to include amelioration of comorbidities, mental health outcomes, quality of life, and social functioning. Current limitations include short trial duration, heterogeneity in outcomes, absence of head-to-head comparisons, and limited long-term safety data, particularly regarding growth, pubertal progression, bone health, and neurocognitive development. Ongoing sponsored and investigator-initiated studies are expected to fill important gap in knowledge informing safety in younger children, and exploring differential responses in specific phenotypes, including youth with polycystic ovary syndrome or metabolic-associated steatotic liver disease. Adherence and long-term engagement are critical challenges in adolescent populations, underscoring the need for patient-centred care, shared decision-making, and structured frameworks such as the Ask, Assess, Advise, Agree, Assist approach. Robust paediatric-specific evidence is required to guide prioritization, treatment algorithms, and personalization of obesity management medication therapy. A balanced, holistic, and evidence-based approach is required to optimize outcomes and reduce lifelong obesity-related morbidity.

Zitieren

APA

Equitani, G., & Manco, M. (2026). Challenges and future directions for the use of GLP-1 receptor agonists in children and adolescents living with obesity. Obesity and Endocrinology, 2(1). https://doi.org/10.1093/obendo/wjag009

Vancouver

Equitani G, Manco M. Challenges and future directions for the use of GLP-1 receptor agonists in children and adolescents living with obesity. Obesity and Endocrinology. 2026;2(1). doi:10.1093/obendo/wjag009

BibTeX
@article{Equitani2026,
  author = {Equitani, Giulio and Manco, Melania},
  title = {Challenges and future directions for the use of GLP-1 receptor agonists in children and adolescents living with obesity},
  journal = {Obesity and Endocrinology},
  year = {2026},
  volume = {2},
  number = {1},
  doi = {10.1093/obendo/wjag009}
}
Kostenlos starten →